Stem cell treatment for acute myocardial infarction

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Stem cell therapy is a promising regenerative approach for cardiac and vascular tissue post-myocardial infarction (MI).
• Numerous randomized controlled trials (RCTs) have investigated stem cell efficacy globally.

Purpose of the Study:

• To critically evaluate existing RCT evidence on the effectiveness of adult bone marrow-derived stem cells (BMSC) for treating acute myocardial infarction (AMI).
• To assess the safety and efficacy of BMSC in patients with acute MI.

Main Methods:

• Comprehensive literature search of MEDLINE, EMBASE, Cochrane Library, CINAHL, LILACS, KOREAMED, INMED, and trial registers up to August 2007.
• Inclusion of RCTs comparing autologous stem/progenitor cells versus no cell treatment in acute myocardial infarction patients.
• Independent data extraction and quality assessment by two reviewers, followed by random-effects meta-analysis and heterogeneity exploration.

Main Results:

• Thirteen RCTs involving 811 participants were analyzed.
• Insufficient data on mortality and adverse events preclude definitive conclusions on safety and clinical outcomes.
• Consistent short-term improvements in left ventricular ejection fraction (LVEF) were observed with BMSC treatment, alongside positive trends in ventricular volumes, infarct size, and wall motion.
• A positive correlation was noted between infused cell dose and LVEF improvement, particularly when measured by MRI.

Conclusions:

• Current evidence is insufficient to fully assess the clinical effects of BMSC therapy for acute MI.
• Larger, well-designed trials employing optimal dosing strategies and patient-centered outcomes are essential.
• The impact of ongoing trials on overcoming current evidence limitations remains uncertain.